Skip to content

Study · Animal study (in vivo) · mouse · 2019

9 results

Improving mitochondrial function with SS-31 reverses age-related redox stress and improves exercise tolerance in aged mice.

Campbell MD, Campbell MD, Duan J, Samuelson AT, Gaffrey MJ, Merrihew GE, Egertson JD, Wang L, Bammler TK, Moore RJ, White CC, Kavanagh TJ and 6 more

Show all authors

Voss JG, Szeto HH, Rabinovitch PS, MacCoss MJ, Qian WJ, Marcinek DJ

Free radical biology & medicine28 Dec 2018Cited by 131 (Europe PMC)

PMID30597195 (opens in a new tab)PMCIDPMC6588449 (opens in a new tab)DOI10.1016/j.freeradbiomed.2018.12.031 (opens in a new tab)PepBankPUB-30597195
Source linkPubMedAsk about this study
Jump to 9 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study9

9 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Efficacy outcome

    In aged mice, SS‑31 reversed the age-related decline in maximum mitochondrial ATP production in vivo.

    In plain wordsIn aged mice, SS‑31 reversed the age-related drop in maximum mitochondrial ATP production in muscle.

    Peptide
    Elamipretide (SS-31)
    Outcome
    IncreaseMaximum mitochondrial ATP production (ATPmax)
    Study

    mousen: not reported in source

    aged C57BL/6Nia female mice
    Outcome group
    Mitochondrial function · Aging and longevity
    Studied dose
    3 mg/kg/day · 8 weeksAs given in this study (mouse).

    Source sentences

    Summary
    SS-31 reversed age-related decline in maximum mitochondrial ATP production (ATPmax) and coupling of oxidative phosphorylation (P/O).
    1 context sentence
    Summary · context
    Young (5 mo) and aged (26 mo) female C57BL/6Nia mice were treated for 8-weeks with 3 mg/kg/day SS-31.
  2. 02AnimalAnimal study (in vivo)Efficacy outcome

    In aged mice, SS‑31 reversed the age-related decline in coupling of oxidative phosphorylation (P/O).

    In plain wordsIn aged mice, SS‑31 reversed the age-related drop in how efficiently mitochondria turn oxygen into energy.

    Peptide
    Elamipretide (SS-31)
    Outcome
    IncreaseCoupling of oxidative phosphorylation (P/O)
    Study

    mousen: not reported in source

    aged C57BL/6Nia female mice
    Outcome group
    Mitochondrial function · Aging and longevity
    Studied dose
    3 mg/kg/day · 8 weeksAs given in this study (mouse).

    Source sentences

    Summary
    SS-31 reversed age-related decline in maximum mitochondrial ATP production (ATPmax) and coupling of oxidative phosphorylation (P/O).
    1 context sentence
    Summary · context
    Young (5 mo) and aged (26 mo) female C57BL/6Nia mice were treated for 8-weeks with 3 mg/kg/day SS-31.
  3. 03AnimalAnimal study (in vivo)Mechanism

    In treated aged mice, mitochondrial protein expression was either unchanged or reduced despite increased in vivo mitochondrial capacity.

    In plain wordsIn aged mice treated with SS‑31, mitochondrial protein levels were unchanged or lower even though mitochondrial capacity rose.

    Peptide
    Elamipretide (SS-31)
    Outcome
    MixedMitochondrial protein expression
    Study

    mousen: not reported in source

    aged C57BL/6Nia female mice
    Outcome group
    Mitochondrial function · Aging and longevity
    Studied dose
    3 mg/kg/day · 8 weeksAs given in this study (mouse).

    Source sentences

    Summary
    Despite the increased in vivo mitochondrial capacity, mitochondrial protein expression was either unchanged or reduced in the treated aged mice
    1 context sentence
    Summary · context
    Young (5 mo) and aged (26 mo) female C57BL/6Nia mice were treated for 8-weeks with 3 mg/kg/day SS-31.
  4. 04AnimalAnimal study (in vivo)Mechanism

    In aged mice, respiration in permeabilized gastrocnemius fibers was not different between aged and aged plus SS‑31 mice.

    In plain wordsIn aged mice, SS‑31 did not change respiration measured in isolated gastrocnemius muscle fibers compared with untreated aged mice.

    Peptide
    Elamipretide (SS-31)
    Outcome
    No significant changeRespiration in permeabilized gastrocnemius fibers
    Study

    mousen: not reported in source

    aged C57BL/6Nia female mice
    Comparator
    Aged mice without SS-31
    Outcome group
    Mitochondrial function · Musculoskeletal
    Studied dose
    3 mg/kg/day · 8 weeksAs given in this study (mouse).

    Source sentences

    Summary
    respiration in permeabilized gastrocnemius (GAS) fibers was not different between the aged and aged+SS-31 mice.
    1 context sentence
    Summary · context
    Young (5 mo) and aged (26 mo) female C57BL/6Nia mice were treated for 8-weeks with 3 mg/kg/day SS-31.
  5. 05AnimalAnimal study (in vivo)Mechanism

    In aged mice, SS‑31 made the glutathione redox status of skeletal muscle more reduced (less oxidized).

    In plain wordsIn aged mice, SS‑31 shifted the glutathione balance in muscle toward the less oxidized state.

    Peptide
    Elamipretide (SS-31)
    Outcome
    DecreaseGlutathione redox status in aged skeletal muscle
    Study

    mousen: not reported in source

    aged C57BL/6Nia female mice
    Outcome group
    Oxidative stress · Musculoskeletal
    Studied dose
    3 mg/kg/day · 8 weeksAs given in this study (mouse).

    Source sentences

    Summary
    The glutathione redox status was more reduced and thiol redox proteomics indicated a robust reversal of cysteine S-glutathionylation post-translational modifications across the skeletal muscle proteome.
    1 context sentence
    Summary · context
    Young (5 mo) and aged (26 mo) female C57BL/6Nia mice were treated for 8-weeks with 3 mg/kg/day SS-31.
  6. 06AnimalAnimal study (in vivo)Mechanism

    In aged mice, SS‑31 produced a robust reversal of cysteine S-glutathionylation modifications across the skeletal muscle proteome.

    In plain wordsIn aged mice, SS‑31 reversed age-related oxidative changes to proteins across skeletal muscle.

    Peptide
    Elamipretide (SS-31)
    Outcome
    DecreaseCysteine S-glutathionylation across the muscle proteome
    Study

    mousen: not reported in source

    aged C57BL/6Nia female mice
    Outcome group
    Oxidative stress · Musculoskeletal
    Studied dose
    3 mg/kg/day · 8 weeksAs given in this study (mouse).

    Source sentences

    Summary
    The glutathione redox status was more reduced and thiol redox proteomics indicated a robust reversal of cysteine S-glutathionylation post-translational modifications across the skeletal muscle proteome.
    1 context sentence
    Summary · context
    Young (5 mo) and aged (26 mo) female C57BL/6Nia mice were treated for 8-weeks with 3 mg/kg/day SS-31.
  7. 07AnimalAnimal study (in vivo)Efficacy outcome

    In aged mice, the gastrocnemius of SS‑31-treated mice was more fatigue resistant than that of aged controls.

    In plain wordsIn aged mice, SS‑31 made a leg muscle more resistant to fatigue compared with aged controls.

    Peptide
    Elamipretide (SS-31)
    Outcome
    IncreaseGastrocnemius fatigue resistance
    Study

    mousen: not reported in source

    aged C57BL/6Nia female mice
    Comparator
    Aged controls
    Outcome group
    Exercise and physical function · Musculoskeletal
    Studied dose
    3 mg/kg/day · 8 weeksAs given in this study (mouse).

    Source sentences

    Summary
    The gastrocnemius in the age+SS-31 mice was more fatigue resistant with significantly greater mass compared to aged controls.
    1 context sentence
    Summary · context
    Young (5 mo) and aged (26 mo) female C57BL/6Nia mice were treated for 8-weeks with 3 mg/kg/day SS-31.
  8. 08AnimalAnimal study (in vivo)Efficacy outcome

    In aged mice, the gastrocnemius of SS‑31-treated mice had significantly greater mass than that of aged controls.

    In plain wordsIn aged mice, SS‑31 treated leg muscle had greater mass compared with aged controls.

    Peptide
    Elamipretide (SS-31)
    Outcome
    IncreaseGastrocnemius mass
    Study

    mousen: not reported in source

    aged C57BL/6Nia female mice
    Comparator
    Aged controls
    Outcome group
    Exercise and physical function · Musculoskeletal
    Studied dose
    3 mg/kg/day · 8 weeksAs given in this study (mouse).

    Source sentences

    Summary
    The gastrocnemius in the age+SS-31 mice was more fatigue resistant with significantly greater mass compared to aged controls.
    1 context sentence
    Summary · context
    Young (5 mo) and aged (26 mo) female C57BL/6Nia mice were treated for 8-weeks with 3 mg/kg/day SS-31.
  9. 09AnimalAnimal study (in vivo)Efficacy outcome

    In aged mice, SS‑31 significantly increased treadmill endurance compared with both pretreatment and untreated control values.

    In plain wordsIn aged mice, SS‑31 increased treadmill running endurance compared with before treatment and with untreated controls.

    Peptide
    Elamipretide (SS-31)
    Outcome
    IncreaseTreadmill endurance
    Study

    mousen: not reported in source

    aged C57BL/6Nia female mice
    Comparator
    Pretreatment and untreated control values
    Outcome group
    Exercise and physical function · Musculoskeletal
    Studied dose
    3 mg/kg/day · 8 weeksAs given in this study (mouse).

    Source sentences

    Summary
    This contributed to a significant increase in treadmill endurance compared to both pretreatment and untreated control values.
    1 context sentence
    Summary · context
    Young (5 mo) and aged (26 mo) female C57BL/6Nia mice were treated for 8-weeks with 3 mg/kg/day SS-31.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    9 Oct 2026, 18:17 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 02:47 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.